|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stathis A and Moore MJ: Advanced
pancreatic carcinoma: Current treatment and future challenges. Nat
Rev Clin Oncol. 7:163–172. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xu C, Li H, Su C and Li Z: Viral therapy
for pancreatic cancer: Tackle the bad guys with poison. Cancer
Lett. 333:1–8. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hidalgo M: Pancreatic cancer. N Engl J
Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
American Cancer Society: Cancer Facts
& Figures 2009. American Cancer Society; Atlanta, GA: pp.
18–19. 2009
|
|
7
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sarkar FH, Li Y, Wang Z and Kong D:
Pancreatic cancer stem cells and EMT in drug resistance and
metastasis. Minerva Chir. 64:489–500. 2009.PubMed/NCBI
|
|
9
|
Li Y, Kong D, Ahmad A, Bao B and Sarkar
FH: Pancreatic cancer stem cells: Emerging target for designing
novel therapy. Cancer Lett. 338:94–100. 2013. View Article : Google Scholar
|
|
10
|
Tsuji T, Ibaragi S and Hu GF:
Epithelial-mesenchymal transition and cell cooperativity in
metastasis. Cancer Res. 69:7135–7139. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Arumugam T, Ramachandran V, Fournier KF,
Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logsdon CD, McConkey
DJ and Choi W: Epithelial to mesenchymal transition contributes to
drug resistance in pancreatic cancer. Cancer Res. 69:5820–5828.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rasheed ZA, Yang J, Wang Q, Kowalski J,
Freed I, Murter C, Hong SM, Koorstra JB, Rajeshkumar NV, He X, et
al: Prognostic significance of tumorigenic cells with mesenchymal
features in pancreatic adenocarcinoma. J Natl Cancer Inst.
102:340–351. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ali S, Ahmad A, Banerjee S, Padhye S,
Dominiak K, Schaffert JM, Wang Z, Philip PA and Sarkar FH:
Gemcitabine sensitivity can be induced in pancreatic cancer cells
through modulation of miR-200 and miR-21 expression by curcumin or
its analogue CDF. Cancer Res. 70:3606–3617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Singh A and Settleman J: EMT, cancer stem
cells and drug resistance: An emerging axis of evil in the war on
cancer. Oncogene. 29:4741–4751. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Polyak K and Weinberg RA: Transitions
between epithelial and mesenchymal states: Acquisition of malignant
and stem cell traits. Nat Rev Cancer. 9:265–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Iwatsuki M, Mimori K, Yokobori T, Ishi H,
Beppu T, Nakamori S, Baba H and Mori M: Epithelial-mesenchymal
transition in cancer development and its clinical significance.
Cancer Sci. 101:293–299. 2010. View Article : Google Scholar
|
|
17
|
Castellanos JA, Merchant NB and
Nagathihalli NS: Emerging targets in pancreatic cancer:
Epithelial-mesenchymal transition and cancer stem cells. Onco
Targets Ther. 6:1261–1267. 2013.PubMed/NCBI
|
|
18
|
Shin SJ, Kim KO, Kim MK, Lee KH, Hyun MS,
Kim KJ, Choi JH and Song HS: Expression of E-cadherin and uPA and
their association with the prognosis of pancreatic cancer. Jpn J
Clin Oncol. 35:342–348. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li Y, VandenBoom TG II, Kong D, Wang Z,
Ali S, Philip PA and Sarkar FH: Up-regulation of miR-200 and let-7
by natural agents leads to the reversal of
epithelial-to-mesenchymal transition in gemcitabine-resistant
pancreatic cancer cells. Cancer Res. 69:6704–6712. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nagaraj NS, Washington MK and Merchant NB:
Combined blockade of Src kinase and epidermal growth factor
receptor with gemcitabine overcomes STAT3-mediated resistance of
inhibition of pancreatic tumor growth. Clin Cancer Res. 17:483–493.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Raida M, Clement JH, Leek RD, Ameri K,
Bicknell R, Niederwieser D and Harris AL: Bone morphogenetic
protein 2 (BMP-2) and induction of tumor angiogenesis. J Cancer Res
Clin Oncol. 131:741–750. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wakefield LM and Hill CS: Beyond TGFβ:
Roles of other TGFβ superfamily members in cancer. Nat Rev Cancer.
13:328–341. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Carreira AC, Alves GG, Zambuzzi WF,
Sogayar MC and Granjeiro JM: Bone morphogenetic proteins:
Structure, biological function and therapeutic applications. Arch
Biochem Biophys. 561:64–73. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Senturk S, Mumcuoglu M, Gursoy-Yuzugullu
O, Cingoz B, Akcali KC and Ozturk M: Transforming growth
factor-beta induces senescence in hepatocellular carcinoma cells
and inhibits tumor growth. Hepatology. 52:966–974. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ikushima H and Miyazono K: TGFbeta
signalling: A complex web in cancer progression. Nat Rev Cancer.
10:415–424. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kaminska B, Wesolowska A and Danilkiewicz
M: TGF beta signalling and its role in tumour pathogenesis. Acta
Biochim Pol. 52:329–337. 2005.PubMed/NCBI
|
|
27
|
Wharton K and Derynck R: TGFbeta family
signaling: Novel insights in development and disease. Development.
136:3691–3697. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen X, Liao J, Lu Y, Duan X and Sun W:
Activation of the PI3K/Akt pathway mediates bone morphogenetic
protein 2-induced invasion of pancreatic cancer cells Panc-1.
Pathol Oncol Res. 17:257–261. 2011. View Article : Google Scholar
|
|
29
|
Kang MH, Oh SC, Lee HJ, Kang HN, Kim JL,
Kim JS and Yoo YA: Metastatic function of BMP-2 in gastric cancer
cells: The role of PI3K/AKT, MAPK, the NF-κB pathway, and MMP-9
expression. Exp Cell Res. 317:1746–1762. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cano CE, Motoo Y and Iovanna JL:
Epithelial-to-mesenchymal transition in pancreatic adenocarcinoma.
Sci World J. 10:1947–1957. 2010. View Article : Google Scholar
|
|
31
|
Sugiura T, Noguchi Y, Sakurai K and
Hattori C: Protein phosphatase 1H, overexpressed in colon
adenocarcinoma, is associated with CSE1L. Cancer Biol Ther.
7:285–292. 2008. View Article : Google Scholar
|
|
32
|
Lee-Hoeflich ST, Pham TQ, Dowbenko D,
Munroe X, Lee J, Li L, Zhou W, Haverty PM, Pujara K, Stinson J, et
al: PPM1H is a p27 phosphatase implicated in trastuzumab
resistance. Cancer Discov. 1:326–337. 2011. View Article : Google Scholar
|
|
33
|
Aceto N and Bentires-Alj M: On the road to
combinations of targeted therapies: PPM1H phosphatase as a
suppressor of trastuzumab resistance. Cancer Discov. 1:285–286.
2011. View Article : Google Scholar
|
|
34
|
Shen T, Sun C, Zhang Z, Xu N, Duan X, Feng
XH and Lin X: Specific control of BMP signaling and mesenchymal
differentiation by cytoplasmic phosphatase PPM1H. Cell Res.
24:727–741. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Christiansen JJ and Rajasekaran AK:
Reassessing epithelial to mesenchymal transition as a prerequisite
for carcinoma invasion and metastasis. Cancer Res. 66:8319–8326.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mani SA, Guo W, Liao M-J, Eaton EN,
Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et
al: The epithelial-mesenchymal transition generates cells with
properties of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Floor S, van Staveren WC, Larsimont D,
Dumont JE and Maenhaut C: Cancer cells in epithelial-to-mesenchymal
transition and tumor-propagating-cancer stem cells: Distinct,
overlapping or same populations. Oncogene. 30:4609–4621. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Santisteban M, Reiman JM, Asiedu MK,
Behrens MD, Nassar A, Kalli KR, Haluska P, Ingle JN, Hartmann LC,
Manjili MH, et al: Immune-induced epithelial to mesenchymal
transition in vivo generates breast cancer stem cells. Cancer Res.
69:2887–2895. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Shreeram S and Bulavin DV: PPM1H - new kid
on the block. Cancer Biol Ther. 7:293–294. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Leung-Hagesteijn C, Mahendra A,
Naruszewicz I and Hannigan GE: Modulation of integrin signal
transduction by ILKAP, a protein phosphatase 2C associating with
the integrin-linked kinase, ILK1. EMBO J. 20:2160–2170. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gao T, Furnari F and Newton AC: PHLPP: A
phosphatase that directly dephosphorylates Akt, promotes apoptosis,
and suppresses tumor growth. Mol Cell. 18:13–24. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shreeram S, Demidov ON, Hee WK, Yamaguchi
H, Onishi N, Kek C, Timofeev ON, Dudgeon C, Fornace AJ, Anderson
CW, et al: Wip1 phosphatase modulates ATM-dependent signaling
pathways. Mol Cell. 23:757–764. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Derynck R and Zhang YE: Smad-dependent and
Smad-independent pathways in TGF-beta family signalling. Nature.
425:577–584. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Moustakas A and Heldin CH: Non-Smad
TGF-beta signals. J Cell Sci. 118:3573–3584. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gordon KJ, Kirkbride KC, How T and Blobe
GC: Bone morphogenetic proteins induce pancreatic cancer cell
invasiveness through a Smad1-dependent mechanism that involves
matrix metalloproteinase-2. Carcinogenesis. 30:238–248. 2009.
View Article : Google Scholar :
|
|
47
|
Deer EL, González-Hernández J, Coursen JD,
Shea JE, Ngatia J, Scaife CL, Firpo MA and Mulvihill SJ: Phenotype
and genotype of pancreatic cancer cell lines. Pancreas. 39:425–435.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wilentz RE, Iacobuzio-Donahue CA, Argani
P, McCarthy DM, Parsons JL, Yeo CJ, Kern SE and Hruban RH: Loss of
expression of Dpc4 in pancreatic intraepithelial neoplasia:
Evidence that DPC4 inactivation occurs late in neoplastic
progression. Cancer Res. 60:2002–2006. 2000.PubMed/NCBI
|
|
49
|
Chang F, Lee JT, Navolanic PM, Steelman
LS, Shelton JG, Blalock WL, Franklin RA and McCubrey JA:
Involvement of PI3K/Akt pathway in cell cycle progression,
apoptosis, and neoplastic transformation: A target for cancer
chemotherapy. Leukemia. 17:590–603. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Altomare DA and Testa JR: Perturbations of
the AKT signaling pathway in human cancer. Oncogene. 24:7455–7464.
2005. View Article : Google Scholar : PubMed/NCBI
|
